Abstract
Cases of SARS-CoV-2 infection in Manaus, Brazil, resurged in late 2020, despite high levels of previous infection there. Through genome sequencing of viruses sampled in Manaus between November 2020 and January 2021, we identified the emergence and circulation of a novel SARS-CoV-2 variant of concern, lineage P.1, that acquired 17 mutations, including a trio in the spike protein (K417T, E484K and N501Y) associated with increased binding to the human ACE2 receptor. Molecular clock analysis shows that P.1 emergence occurred around early November 2020 and was preceded by a period of faster molecular evolution. Using a two-category dynamical model that integrates genomic and mortality data, we estimate that P.1 may be 1.4–2.2 times more transmissible and 25-61% more likely to evade protective immunity elicited by previous infection with non-P.1 lineages. Enhanced global genomic surveillance of variants of concern, which may exhibit increased transmissibility and/or immune evasion, is critical to accelerate pandemic responsiveness.
One-Sentence Summary We report the evolution and emergence of a SARS-CoV-2 lineage of concern associated with rapid transmission in Manaus.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was supported by a Medical Research Council-Sao Paulo Research Foundation (FAPESP) CADDE partnership award (MR/S0195/1 and FAPESP 18/14389-0) (caddecentre.org/). FAPESP further supports IMC (2018/17176-8 and 2019/12000-1), F.C.S.S. (2018/25468-9), JGJ (2018/17176-8 and 2019/12000-1, 18/14389-0), TMC (2019/07544-2), CAMS (2019/21301-5), WMS (2017/13981-0, 2019/24251-9), LMS (FAPESP 2020/04272-9), MCP (FAPESP 2019/21568-1) and P.S.P. (16/18445-7). N.R.F. is supported by a Wellcome Trust and Royal Society Sir Henry Dale Fellowship (204311/Z/16/Z). DSC is supported by the Clarendon Fund and by the Department of Zoology, University of Oxford. This project was supported by CNPq (RSA: 312688/2017-2 and 439119/2018-9; and WMS: 408338/2018-0), FAPERJ (RSA: 202.922/2018). MSR is supported by FFMUSP (FFMUSP 206.706). HS is supported by Imperial College Covid-19 Research Fund. GMF is supported by CAPES. PL, AR, and NJL are supported by the Wellcome Trust ARTIC network (collaborators award no. 206298/Z/17/Z). PL and AR are supported by the European Research Council (grant no. 725422 -ReservoirDOCS). PL is further supported by the European Unions Horizon 2020 project MOOD (874850). MAS is supported by US National Institutes of Health (U19 AI135995). OGP is supported by the Oxford Martin School. SF is supported by the Imperial College Covid-19 Research Fund and EPSRC (EP/V002910/1). SB is supported by BMGF, UKRI, Novo Nordisk Foundation, Academy of Medical Sciences, BRC and MRC. ECS is supported by FAPESP (18/14389-0). We acknowledge support from the Rede Corona-omica BR MCTI/FINEP affiliated to RedeVirus/MCTI (FINEP 01.20.0029.000462/20, CNPq 404096/2020-4). This work received funding from the U.K. Medical Research Council under a concordat with the U.K. Department for International Development. We additionally acknowledge support from Community Jameel and the NIHR Health Protection Research Unit in Modelling Methodology.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this study was confirmed by the national ethical review board (Comissao Nacional de Etica em Pesquisa), protocol number CAAE 30127020.0.0000.0068.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Preliminary genome sequences generated from samples obtained from laboratory A were shared on GISAID on 12 January 2021. Findings were shared with representatives from the World Health Organization, Pan American Health Organization, Secretary of Health Amazonas, and FioCruz Manaus on 11 January 2021. Preliminary report describing first P.1 genomes from Manaus was shared on 12 January 2021 (86). Epidemiological data and epidemiological model code, together with BEAST XML files, tree files, log files are archived at https://github.com/CADDE-CENTRE. GISAID IDs for the SARS-CoV-2 Manaus sequence data can be found in Data S2. All consensus sequences generated by this study can be found at https://github.com/CADDE-CENTRE.
